NCT07901868
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07901868
Title Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (GEM-MeziDEL)
Acronym GEM-MeziDEL
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors PETHEMA Foundation
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.